InMed Pharmaceuticals is pleased to welcome to the BayMedica team following its acquisition in October 2021.
Meet Philip Barr, our VP of Discovery Research. Phil talks about his career history which includes his role at Chiron Corporation – a company involved in cloning the HIV and Hepatitis C viruses for which one of the scientific leaders received a Nobel Prize. Phil’s extensive experience includes expertise in molecular biology, organic chemistry and yeast biosynthesis. He later became the CEO of Arriva Pharmaceuticals where he spearheaded the development of recombinant human alpha 1-antitrypsin for hereditary emphysema. Phil eventually co-founded BayMedica.